SCHEMBL6607611

SCHEMBL6607611

COC(=O)c1ccc2cc(-c3ccc([C]4CCCCS4(=O)=O)s3)ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
CYP19A1 P11511 1/20 0.42
SLC6A2 P23975 3/20 0.40
SLC6A3 Q01959 2/20 0.40
PLAU P00749 4/20 0.38
PTPN11 Q06124 2/20 0.38
PLAT P00750 2/20 0.38
PLG P00747 1/20 0.38
HDAC1 Q13547 1/20 0.37
LCK P06239 1/20 0.36
RARA P10276 2/20 0.36
RARB P10826 2/20 0.36
RARG P13631 2/20 0.36
HDAC6 Q9UBN7 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6836173 0.81 HSD17B1 (0.40)
SCHEMBL5224416 0.80 APP (0.56) CYP11B1CYP11B2CYP19A1PLAUPTPN11
SCHEMBL6609753 0.79 APP (0.35) CYP11B1CYP11B2
SCHEMBL6610877 0.79 GALR1 (0.42) CYP11B1CYP11B2CYP19A1TP53SMN1; SMN2
SCHEMBL5227376 0.73 PLAU (0.56) CYP11B1CYP11B2CYP19A1PLAUPTPN11
SCHEMBL6840579 0.72 CYP19A1 (0.37) CYP11B1CYP11B2CYP19A1SLC6A2SLC6A3
SCHEMBL13900228 0.72 CYP11B1 (0.69) CYP11B1CYP11B2CYP19A1SLC6A2SLC6A3
SCHEMBL5227115 0.71 CYP19A1 (0.44) CYP11B1CYP11B2CYP19A1PLAUPTPN11
SCHEMBL5227109 0.71 PLAU (0.48) CYP11B1CYP11B2CYP19A1PLAUPTPN11
SCHEMBL69025 0.68 PTPN11 (0.68) CYP11B1CYP11B2CYP19A1PLAUPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed
EP-1423386-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP disclosed
WO-2003022842-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors TNF, MMP9, MMP1 CYP11B1 1192/4885CYP11B2 1426/4885CYP19A1 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.